Jeng Long-Bin, Yang Horng-Ren, Teng Chiao-Fang
Organ Transplantation Center, China Medical University Hospital, Taichung, 404, Taiwan.
Department of Surgery, China Medical University Hospital, Taichung, 404, Taiwan.
Discov Oncol. 2025 Sep 2;16(1):1674. doi: 10.1007/s12672-025-03309-1.
Although significant advances have been made in the prevention and therapy, hepatocellular carcinoma (HCC) is still one of the most frequent and fatal human cancers worldwide. Discovery of independent prognostic biomarkers for the early identification and timely treatment of HCC patients with poor prognosis remains a key goal to achieve better patient survival. Long non-coding RNA (lncRNA) is one of the most-investigated classes of non-coding RNAs and plays important roles in controlling the occurrence and development of HCC through regulation of oncogene and tumor suppressor gene expression. Moreover, alterations in the expression levels of many lncRNAs are frequently observed in tumor tissues and blood circulation of HCC patients. LncRNAs have emerged as potential independent biomarkers for predicting the prognosis of HCC patients. This review comprehensively summarizes the evidence in the literature validating a single or a combination of lncRNA biomarker(s) with independent prognostic value in HCC patients.
尽管在预防和治疗方面取得了重大进展，但肝细胞癌（HCC）仍然是全球最常见且致命的人类癌症之一。发现独立的预后生物标志物以早期识别并及时治疗预后不良的HCC患者，仍然是实现更好患者生存的关键目标。长链非编码RNA（lncRNA）是研究最多的非编码RNA类别之一，通过调控癌基因和肿瘤抑制基因的表达，在控制HCC的发生和发展中发挥重要作用。此外，在HCC患者的肿瘤组织和血液循环中经常观察到许多lncRNA表达水平的改变。LncRNAs已成为预测HCC患者预后的潜在独立生物标志物。本综述全面总结了文献中的证据，这些证据验证了lncRNA生物标志物单一或组合在HCC患者中具有独立预后价值。
